Anti-Obesity Drugs Are On The Come Up In A $44 Billion Market By 2030

... Obesity stands as a significant public health issue in the United States, disproportionately affecting racial and ethnic minority communities. Approximately 71 million adults in the U.S., or one-third of the total adult population, were classified as obese. Particularly, the Black community bears the brunt of this health crisis as 49% of adults in this demographic qualify as obese.

While these drugs present a potential solution to the obesity crisis, their high cost poses a significant barrier to access. TheseWeight loss drug makers Ozempic and Wegovy have been courting influential Black leaders to plead their Medicare coverage case. They enlisted Black music and entertainment stars Queen Latifah and.

Expanding Medicare coverage to include these new classes of weight loss drugs could significantly reduce healthcare costs, according to a recent white paper by the USC Schaeffer Center. The paper estimates that treating obesity could generatein the first decade alone, increasing to $700 billion in 30 years. If all eligible Americans were treated, the prevalence of obesity in the Medicare population would fall by 53% after the first decade.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Johnson & Johnson beats earnings estimates, downplays obesity drugs’ impact on its med-tech businessCompany raises full-year profit and sales guidance and pursues multipronged strategy to address talc-powder litigation
La source: MarketWatch - 🏆 3. / 97 Lire la suite »